BioPorto A/S to host first quarter 2025 earnings webcast for investors

About this update from Bioporto A/s

[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"  ","length":12,"tagName":"p"},{"type":"text","content":"April 28, 2025","length":14,"tagName":"p"},{"type":"text","content":"News release","length":12,"tagName":"p"},{"type":"text","content":"BioPorto A/S to host first quarter 2025 earnings webcast for investors","length":70,"tagName":"p"},{"type":"text","content":"COPENHAGEN, DENMARK, April 28, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter 2025, CFO Niels Høy Nielsen will present financial results for Q1 2025 at a webcast for investors on May 8 at 1:00 PM.","length":427,"tagName":"p"},{"type":"text","content":"Registration for the presentation is now open, and participants can submit questions in advance. Please register at the following link: https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2025 ","length":199,"tagName":"p"},{"type":"text","content":"For further information, please contact:","length":40,"tagName":"p"},{"type":"text","content":"Hanne S. Foss, Head of Investor Relations, BioPorto A/S, [email protected], C: +45 26368918","length":95,"tagName":"p"},{"type":"text","content":"About BioPorto","length":14,"tagName":"p"},{"type":"text","content":"BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s test...

More updates from Bioporto A/s